Literature DB >> 28630205

Impact of gyrB and eis Mutations in Improving Detection of Second-Line-Drug Resistance among Mycobacterium tuberculosis Isolates from Georgia.

N Bablishvili1, N Tukvadze2, E Shashkina3, B Mathema4, N R Gandhi5,6, H M Blumberg5, R R Kempker5.   

Abstract

The country of Georgia has a high burden of multi- and extensively drug-resistant tuberculosis (XDR-TB). To evaluate whether mutations in gyrB and eis genes increased the sensitivity of detection of phenotypic resistance to ofloxacin and kanamycin or capreomycin compared to use of the first-generation MTBDRsl assay alone, which tests for mutations in gyrA and rrs genes, a retrospective study of stored Mycobacterium tuberculosis isolates was performed. All isolates underwent DNA sequencing of resistance-determining regions. Among 112 M. tuberculosis isolates with DNA extraction data, targeted sequencing was successfully performed for each gene as follows: for gyrA, 98% sensitivity; for gyrB, 96%; for rrs, 93%; for the eis gene and its promoter, 93%. The specificity and hence the positive predictive value of gyrA and gyrB mutations for detecting ofloxacin resistance were 100%. The addition of gyrB mutations increased the sensitivity of phenotypic ofloxacin resistance detection by 13% (75% to 88%). All rrs resistance-conferring mutations were A1401G, and this mutation had low sensitivity (40% and 18%) and high specificity (95% and 100%) in predicting phenotypic capreomycin and kanamycin resistance, respectively. The eis C-14T mutation increased the sensitivity of phenotypic kanamycin resistance detection by 9% (18% to 27%) and was found solely in kanamycin phenotypic resistance isolates. Our data showed that the inclusion of eis C-14T and gyrB mutations in addition to rrs and gyrA mutations improves the sensitivity of detection of phenotypic ofloxacin and kanamycin resistance, respectively.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  DNA sequencing; Georgia; drug resistant; eis; gyrB

Mesh:

Substances:

Year:  2017        PMID: 28630205      PMCID: PMC5571295          DOI: 10.1128/AAC.01921-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  The role of eis mutations in the development of kanamycin resistance in Mycobacterium tuberculosis isolates from the Moscow region.

Authors:  Marina B Gikalo; Elena Y Nosova; Ludmila Y Krylova; Arkadyi M Moroz
Journal:  J Antimicrob Chemother       Date:  2012-05-16       Impact factor: 5.790

2.  Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis.

Authors:  M Analise Zaunbrecher; R David Sikes; Beverly Metchock; Thomas M Shinnick; James E Posey
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-11       Impact factor: 11.205

3.  Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations.

Authors:  Timothy C Rodwell; Faramarz Valafar; James Douglas; Lishi Qian; Richard S Garfein; Ashu Chawla; Jessica Torres; Victoria Zadorozhny; Min Soo Kim; Matt Hoshide; Donald Catanzaro; Lynn Jackson; Grace Lin; Edward Desmond; Camilla Rodrigues; Kathy Eisenach; Thomas C Victor; Nazir Ismail; Valeru Crudu; Maria Tarcela Gler; Antonino Catanzaro
Journal:  J Clin Microbiol       Date:  2013-12-18       Impact factor: 5.948

Review 4.  Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis.

Authors:  Keertan Dheda; Tawanda Gumbo; Neel R Gandhi; Megan Murray; Grant Theron; Zarir Udwadia; G B Migliori; Robin Warren
Journal:  Lancet Respir Med       Date:  2014-03-24       Impact factor: 30.700

Review 5.  Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement.

Authors:  J Domínguez; E C Boettger; D Cirillo; F Cobelens; K D Eisenach; S Gagneux; D Hillemann; R Horsburgh; B Molina-Moya; S Niemann; E Tortoli; A Whitelaw; C Lange
Journal:  Int J Tuberc Lung Dis       Date:  2016-01       Impact factor: 2.373

6.  Significant clinical impact of a rapid molecular diagnostic test (Genotype MTBDRplus assay) to detect multidrug-resistant tuberculosis.

Authors:  Maia Kipiani; Veriko Mirtskhulava; Nestani Tukvadze; Matthew Magee; Henry M Blumberg; Russell R Kempker
Journal:  Clin Infect Dis       Date:  2014-08-04       Impact factor: 9.079

7.  Rifampin heteroresistance in Mycobacterium tuberculosis cultures as detected by phenotypic and genotypic drug susceptibility test methods.

Authors:  Dorte Bek Folkvardsen; Vibeke Ø Thomsen; Leen Rigouts; Erik Michael Rasmussen; Didi Bang; Gertjan Bernaerts; Jim Werngren; Juan Carlos Toro; Sven Hoffner; Doris Hillemann; Erik Svensson
Journal:  J Clin Microbiol       Date:  2013-09-25       Impact factor: 5.948

8.  Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis.

Authors:  Maha R Farhat; Karen R Jacobson; Molly F Franke; Devinder Kaur; Alex Sloutsky; Carole D Mitnick; Megan Murray
Journal:  J Clin Microbiol       Date:  2016-01-13       Impact factor: 5.948

Review 9.  Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review.

Authors:  Sophia B Georghiou; Marisa Magana; Richard S Garfein; Donald G Catanzaro; Antonino Catanzaro; Timothy C Rodwell
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

10.  The EMBL-EBI bioinformatics web and programmatic tools framework.

Authors:  Weizhong Li; Andrew Cowley; Mahmut Uludag; Tamer Gur; Hamish McWilliam; Silvano Squizzato; Young Mi Park; Nicola Buso; Rodrigo Lopez
Journal:  Nucleic Acids Res       Date:  2015-04-06       Impact factor: 16.971

View more
  4 in total

1.  Frequency of first and second-line drug resistance-associated mutations among resistant Mycobacterium tuberculosis clinical isolates from São Paulo, Brazil.

Authors:  Tania Matsui; Juliana Maíra Watanabe Pinhata; Michelle Christiane da Silva Rabello; Angela Pires Brandão; Lucilaine Ferrazoli; Sylvia Cardoso Leão; Cristina Viana-Niero; Rosangela Siqueira de Oliveira
Journal:  Mem Inst Oswaldo Cruz       Date:  2020-05-08       Impact factor: 2.743

2.  Performance of Genotype MTBDRsl V2.0 over the Genotype MTBDRsl V1 for detection of second line drug resistance: An Indian perspective.

Authors:  Syed Beenish Rufai; Kulsum Umay; Praveen Kumar Singh; Sarman Singh
Journal:  PLoS One       Date:  2020-03-04       Impact factor: 3.240

3.  Xpert MTB/RIF Use Is Associated With Earlier Treatment Initiation and Culture Conversion Among Patients With Sputum Smear-Negative Multidrug-Resistant Tuberculosis.

Authors:  Maia Kipiani; Daniel S Graciaa; Mariana Buziashvili; Lasha Darchia; Zaza Avaliani; Nino Tabagari; Veriko Mirtskhulava; Russell R Kempker
Journal:  Open Forum Infect Dis       Date:  2021-11-06       Impact factor: 4.423

4.  Molecular Epidemiology and Polymorphism Analysis in Drug-Resistant Genes in M. tuberculosis Clinical Isolates from Western and Northern India.

Authors:  Vibhuti Rana; Nittu Singh; Chaitali Nikam; Priti Kambli; Pravin K Singh; Urmila Singh; Amita Jain; Camilla Rodrigues; Charu Sharma
Journal:  Infect Drug Resist       Date:  2022-04-08       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.